These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 26068539)

  • 101. Recurrent venous thromboembolism during anticoagulation with edoxaban or warfarin: A post hoc analysis of the Hokusai-VTE trial.
    Eichinger S; Lin M; Shi M; Grosso MA; Kyrle PA
    Thromb Res; 2020 Nov; 195():209-214. PubMed ID: 32750571
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Edoxaban for the prevention of thromboembolic events after surgery.
    Gras J
    Drugs Today (Barc); 2011 Oct; 47(10):753-61. PubMed ID: 22076490
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Elderly patients with atrial fibrillation in routine clinical practice-peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study.
    Unverdorben M; von Heymann C; Santamaria A; Saxena M; Vanassche T; Jin J; Laeis P; Wilkins R; Chen C; Colonna P
    BMC Cardiovasc Disord; 2020 Dec; 20(1):504. PubMed ID: 33256590
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
    Beyer-Westendorf J; Ageno W
    Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
    Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
    J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
    Arepally GM; Ortel TL
    Annu Rev Med; 2015; 66():241-53. PubMed ID: 25587651
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Target-specific oral anticoagulants and the hospitalist.
    Deitelzweig S; Amin A
    Hosp Pract (1995); 2015; 43(1):1-12. PubMed ID: 25559350
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism.
    Vandell AG; Walker J; Brown KS; Zhang G; Lin M; Grosso MA; Mercuri MF
    Heart; 2017 Nov; 103(22):1800-1805. PubMed ID: 28689179
    [TBL] [Abstract][Full Text] [Related]  

  • 109. [Edoxaban in patients with atrial fibrillation and cancer].
    Maurea N; Riva L
    G Ital Cardiol (Rome); 2018 Sep; 19(9 Suppl 1):13S-19S. PubMed ID: 30284558
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Effectiveness and safety of oral direct factor Xa inhibitors for the treatment of venous thromboembolism in patients with cancer and/or older age.
    Sato D; Ikeda S; Koga S; Yamagata Y; Eguchi M; Yonekura T; Tsuneto A; Yoshimuta T; Koide Y; Kawano H; Maemura K
    Heart Vessels; 2019 Apr; 34(4):678-687. PubMed ID: 30341629
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Clinical Pharmacology and Role of Edoxaban in Contemporary Antithrombotic Therapy.
    Switzer MP; Wani P; Gosavi S; Mukherjee D
    Cardiovasc Hematol Agents Med Chem; 2015; 13(2):98-104. PubMed ID: 26695421
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa.
    Parasrampuria DA; Truitt KE
    Clin Pharmacokinet; 2016 Jun; 55(6):641-55. PubMed ID: 26620048
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT-AF/VTE study.
    Colonna P; von Heymann C; Santamaria A; Saxena M; Vanassche T; Wolpert D; Laeis P; Wilkins R; Chen C; Unverdorben M
    Clin Cardiol; 2020 Jul; 43(7):769-780. PubMed ID: 32406557
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
    Ma G; Zhang R; Wu X; Wang D; Ying K
    Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Factor Xa and thrombin as targets for new oral anticoagulants.
    Weitz JI
    Thromb Res; 2011 Jan; 127 Suppl 2():S5-S12. PubMed ID: 21193114
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin.
    Fuji T; Ochi T; Niwa S; Fujita S
    J Orthop Sci; 2008 Sep; 13(5):442-51. PubMed ID: 18843459
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Is it reasonable to use a lower DOAC dose in some patients with VTE? NO.
    Dentali F; Fantoni C
    Intern Emerg Med; 2017 Aug; 12(5):565-567. PubMed ID: 28656545
    [TBL] [Abstract][Full Text] [Related]  

  • 118. The use of factor Xa inhibitors following opening-wedge high tibial osteotomy for venous thromboembolism prophylaxis.
    Kobayashi H; Akamatsu Y; Kumagai K; Kusayama Y; Ishigatsubo R; Mitsuhashi S; Kobayashi A; Aratake M; Saito T
    Knee Surg Sports Traumatol Arthrosc; 2017 Sep; 25(9):2929-2935. PubMed ID: 27000391
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Real-world Safety and Effectiveness of Edoxaban in Patients with Venous Thromboembolism with or without Preceding Parenteral Anticoagulants: A Single-center Retrospective Study.
    Ueno Y; Ikeda S; Motokawa T; Honda T; Kurobe M; Akashi R; Yonekura T; Yoshimuta T; Eguchi M; Kawano H; Maemura K
    Intern Med; 2024 Jul; 63(13):1845-1853. PubMed ID: 37981306
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.
    Duggan ST
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):57-72. PubMed ID: 22272729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.